Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains

Veradermics Inc. (NYSE:MANE) announced on Monday that its novel oral formulation, VDPHL01, achieved positive results in a Phase 2/3 trial for pattern hair loss.

Hair Growth Gains And Patient Response Metrics

The development positions the treatment as a potential first FDA-approved oral pill for hair loss in nearly 30 years.

• Hair Growth Increase: 30.3 hairs/cm² (once daily) and 33.0 hairs/cm² (twice daily) compared to 7.3 hairs/cm² for placebo.
• Patient Improvement: 79.3% (once daily) and 86.0% (twice daily) reported improvement versus 35.6% for placebo.
• Safety Profile: No treatment-related serious adverse events; adverse event rates similar to placebo.

The trial enrolled 519 patients and demonstrated significant hair growth with VDPHL01, a proprietary extended-release oral minoxidil.

The treatment showed a rapid onset of action and consistent patient response, with no cardiac-related adverse events reported.

Following 6 months of treatment with VDPHL01, 79.3% of patients in the once daily dose arm and 86.0% of patients in the twice daily dose arm reported improvement in hair coverage on the AAIRS versus 35.6% of placebo patients.

Additionally, 48.4% of patients in the once daily dose arm and 62.9% of patients in the twice daily dose arm achieved ‘improved’ or ‘much improved’ hair coverage on the AAIRS compared to only 13.4% of placebo patients.

Expert View And Market Opportunity

Dr. Maryanne Makredes Senna from Beth Israel Lahey Health noted the potential of VDPHL01 to transform the treatment landscape for male pattern hair loss.

The trial results indicated improved hair loss in nearly 80% of patients, highlighting the formulation’s efficacy and safety.

Veradermics, the aesthetic and dermatology company, is advancing its pivotal development program, with additional trials underway for both male and female pattern hair loss.

The company aims to address the significant unmet need in the hair loss market, which affects an estimated 80 million people in the U.S.

IPO Proceeds And Development Runway

The company closed its upsized initial public offering in February 2026, and the company raised gross proceeds of approximately $294.8 million.

The net proceeds from the offering, together with the company’s current cash, cash equivalents, and marketable securities, are expected to support Veradermics’ current operating plans into 2029, which include multiple anticipated Phase 3 readouts and the anticipated commercial launch of VDPHL01, if approved.

MANE Price Action: Veradermics shares were up 34.34% at $91.13 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.

Photo: Alopecia-Photo via Shutterstock